Using Tolerance Intervals to Assess Conformance to Requirements

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology, December 2021 Issue
Volume 45
Issue 12
Pages: 38–42

The authors introduce the idea of asymmetrical tolerance intervals as an aid in fully assessing product performance relative to product or process requirements.

Paulista - Stock.adobe.com

Paulista - Stock.adobe.com

Unused, misused, or misunderstood, statistical tolerance intervals are fundamentally different from statistical confidence intervals, which provide interval estimates for summary statistics, such as mean and standard deviation. Tolerance intervals were developed as a tool to provide confidence intervals for a population proportion. With insights gained, the tolerance interval can be effectively used to develop product and process specifications as well as determine conformance to requirements.

Statistical tolerance intervals are routinely used to assess a product’s conformance to requirements and to provide a range within which one can expect product attributes to be contained. In this paper, the authors focus on parametric tolerance intervals that assume normally distributed data. The authors introduce the idea of asymmetrical tolerance intervals as an aid in fully assessing product performance relative to product or process requirements.Tolerance intervals are generated by collecting data through sampling of representative product and processes and using tolerance interval factors (k) to create the tolerance limits. Tolerance interval factors are widely available in tables and available in many statistical computer programs.

Click here for a PDF of the article.

About the authors

Lynn D. Torbeck is a statistician with Torbeck and Associates. Chuck Pheatt is Professor Emeritus with Emporia State University.

Article Details

Pharmaceutical Technology
Volume 45, Number 12
December 2021
Page: 38–42

Citation

When referring to this article, please cite it as L. D. Torbeck and C. Pheatt, “Using Tolerance Intervals to Assess Conformance to Requirements,” Pharmaceutical Technology 45 (12) 2021.

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content